CD274 and neoplasm: The phase 3 IMpassion130 study showed a clinical benefit with atezolizumab (an anti–PD-L1 antibody) plus chemotherapy versus chemotherapy alone in patients with locally advanced or metastatic TNBC with PD-L1 expression on tumor-infiltrating immune cells (PD-L1 IC+) but not in the intent-to-treat population (ie, irrespective of PD-L1 IC status)17.